Differential Signaling Pathways in Medulloblastoma: Nano-biomedicine Targeting Non-coding Epigenetics to Improve Current and Future Therapeutics
Sokolov, Daniil; Sharda, Neha; Banerjee, Aindrila; Denisenko, Kseniia; Basalious, Emad B; Shukla, Hem; Waddell, Jaylyn; Prof. Hamdy, Nadia M.; Banerjee, Aditi;
Abstract
Medulloblastomas (MDB) are malignant, aggressive brain tumors that primarily affect children. The survival rate for children under 14 is approximately 72%, while for ages 15 to 39, it is around 78%. A growing body of evidence suggests that dysregulation of signaling mechanisms and noncoding RNA epigenetics play a pivotal role in this disease.
Other data
| Title | Differential Signaling Pathways in Medulloblastoma: Nano-biomedicine Targeting Non-coding Epigenetics to Improve Current and Future Therapeutics | Authors | Sokolov, Daniil; Sharda, Neha; Banerjee, Aindrila; Denisenko, Kseniia; Basalious, Emad B; Shukla, Hem; Waddell, Jaylyn; Prof. Hamdy, Nadia M. ; Banerjee, Aditi | Keywords | Medulloblastoma (MDB); disease-hallmarks; epigenetics; in silico; nanomedicine; nanoparticles.; nanotechnology; ncRNA; signaling mechanisms; targeted therapies | Issue Date | 2024 | Journal | Current pharmaceutical design | ISSN | 13816128 | DOI | 10.2174/0113816128277350231219062154 | PubMed ID | 38151840 | Scopus ID | 2-s2.0-85182858005 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.